5 January 2024
CVS Group Plc
("CVS" or the "Company")
Correction of Exercise of Options, PDMR Dealing
and Total Voting Rights
CVS, one of the UK's leading providers of integrated veterinary services, corrects its previous announcement and confirms that on 4 January 2024, options over a total of 148,032 ordinary shares of 0.2 pence each (the "Ordinary Shares") were exercised under the CVS Group 2020 SAYE Plan (2020/2024) and 6,733 Ordinary Shares under the CVS Group Long Term Incentive Plan 2020 ("LTIP 14").
The sum of 148,032 new Ordinary Shares were issued to satisfy the balance of Ordinary Shares arising from the SAYE Exercise at an exercise price of £10.09. Admission of the 148,032 new Ordinary Shares has been satisfied by the Company's block listing admitted to the London Stock Exchange on 30 December 2021.
Robin Alfonso, Chief Financial Officer exercised options over 606 Ordinary Shares in the Company under the SAYE plan. The balance of the options were exercised by certain other employees and former employees of the Company.
Robin Alfonso additionally exercised options over 6,733 Ordinary Shares under the LTIP 14 scheme. The issuance of shares in connection with the LTIP 14 exercise was fully satisfied by 6,733 Ordinary Shares held by the CVS Group Employee Benefit Trust (the "EBT").
On 4 January 2024, the Company was notified that Robin Alfonso sold 3,218 Ordinary Shares at the price of £16.17 each to meet the costs of exercise incurred as a PDMR option-holder, including personal taxation.
Following his option exercises and sale of Ordinary Shares, Robin Alfonso together with any persons closely associated holds a beneficial interest in 23,373 Ordinary Shares in the Company, representing approximately 0.033% of the total voting rights of the Company, calculated on the same basis.
Following the issue of the new Ordinary Shares, the Company has a total issued share capital of 71,685,694 Ordinary Shares each carrying one voting right. The Company holds no Ordinary Shares in treasury. Therefore, following the issue of the new Ordinary Shares, the total number of voting rights in the Company will be 71,685,694. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.
Contacts:
CVS Group plc via Camarco
Richard Fairman, CEO
Scott Morrison, Company Secretary
Peel Hunt LLP (Nominated Adviser & Broker) +44 (0)20 7418 8900
Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose
Berenberg (Joint Broker) +44 (0)20 3207 7800
Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser
Camarco (Financial PR)
Geoffrey Pelham-Lane +44 (0)7733 124 226
Ginny Pulbrook +44 (0)7961 315 138
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Robin Alfonso |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Financial Officer |
| b) | Initial notification /Amendment | Initial Notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | CVS Group plc |
| b) | LEI | 213800J41XDQ2NX48O05 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 0.2 pence each
GB00B2863827 | ||||||||||
| b) | Nature of the transaction | a) Exercise of options under the 2020 SAYE Plan (1 January 2024 maturity) b) Exercise of options under the CVS Group Long Term Incentive Plan 2020 (4 January 2024 maturity) c) Sale of Ordinary shares arising from exercise
| ||||||||||
| c) | Price(s) and volume(s) |
| ||||||||||
| d) | Aggregated information
- Aggregated volume
- Price |
N/A | ||||||||||
| e) | Date of the transaction | a) 4 January 2024 b) 4 January 2024 | ||||||||||
| f) | Place of the transaction | a) London Stock Exchange - AIM b) London Stock Exchange - AIM |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.